-+ 0.00%
-+ 0.00%
-+ 0.00%
Greenwich LifeSciences secures SABCS 2026 acceptance for two Phase III breast cancer trial abstracts
Share
Listen to the news
Greenwich LifeSciences secures SABCS 2026 acceptance for two Phase III breast cancer trial abstracts
  • Greenwich LifeSciences will present two posters on its Phase III FLAMINGO-01 trial at the San Antonio Breast Cancer Symposium on December 9, 2026.
  • Both corresponding abstracts were accepted for publication at the conference, scheduled for December 8-11.
  • The trial evaluates Fast Track-designated GLSI-100, an immunotherapy intended to prevent breast cancer recurrence.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Greenwich Lifesciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170600PRIMZONEFULLFEED9878607) on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending